| GPNMB: a potent inducer of immunosuppression in cancer AM Lazaratos, MG Annis, PM Siegel Oncogene 41 (41), 4573-4590, 2022 | 33 | 2022 |
| Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases AM Lazaratos, SM Maritan, A Quaiattini, A Darlix, I Ratosa, E Ferraro, ... The Breast 69, 451-468, 2023 | 16 | 2023 |
| FIRRM cooperates with FIGNL1 to promote RAD51 disassembly during DNA repair E Pinedo-Carpio, J Dessapt, A Beneyton, L Sacre, MA Bérubé, R Villot, ... Science Advances 9 (32), eadf4082, 2023 | 8 | 2023 |
| Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis DJH Bian, AM Lazaratos, SM Maritan, A Quaiattini, Z Zeng, Z Zhu, ... Heliyon 10 (9), 2024 | 3 | 2024 |
| C1orf112 is a novel regulator of interstrand crosslink that decreases FIGNL1-RAD51 interaction E Pinedo-Carpio, J Dessapt, R Villot, L Sacre, A Malina, J Boulais, ... bioRxiv, 2022.10. 06.511186, 2022 | 1 | 2022 |
| The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre AM Lazaratos, M Dankner, A Hamouda, S Labidi, V Cohen, L Panasci, ... Current Oncology 32 (1), 1, 2024 | | 2024 |
| Antibody–Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases DJH Bian, SF Cohen, AM Lazaratos, N Bouganim, M Dankner Current Oncology 31 (10), 6314, 2024 | | 2024 |
| CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer AM Lazaratos, K Petrecca, MC Guiot, KJ Jerzak, M Dankner The Lancet Oncology 25 (7), e282, 2024 | | 2024 |
| 12P The prognostic significance of BRAF mutations in early-stage colon cancer LR Dubé, M Dankner, A Stein, A Nowakowski, L Park, J Magrill, ... Annals of Oncology 35, S7, 2024 | | 2024 |
| Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers M Dankner, E Rousselle, S Petrecca, F Fabi, A Nowakowski, ... medRxiv, 2024.03. 23.24304779, 2024 | | 2024 |
| An individual patient-level meta-analysis of non–small-cell lung cancer leptomeningeal metastases treated with epidermal growth factor receptor inhibitors. DJ Bian, AM Lazaratos, SM Maritan, A Quaiattini, Z Zeng, Z Zhu, U Sener, ... Journal of Clinical Oncology 41 (16_suppl), e21118-e21118, 2023 | | 2023 |
| A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases. AM Lazaratos, SM Maritan, A Darlix, I Ratosa, E Ferraro, G Griguolo, ... Journal of Clinical Oncology 41 (16_suppl), 2034-2034, 2023 | | 2023 |
| Targeting tumor-brain crosstalk in invasive brain metastases C Mourcos, SM Maritan, MG Annis, G Kruck, A Nowakowski, ... Cancer Research 83 (7_Supplement), 3615-3615, 2023 | | 2023 |
| SYST-05 OPTIMIZING HER2-TARGETED THERAPIES (TT) FOR BREAST CANCER (BC) LEPTOMENINGEAL METASTASES (LM): A SYSTEMATIC REVIEW AND META-ANALYSIS AM Lazaratos, S Maritan, A Quaiattini, N Bouganim, M Dankner Neuro-Oncology Advances 4 (Supplement_1), i21-i22, 2022 | | 2022 |
| Osimertinib is Associated with Improved Outcomes Versus First-and Second-Generation Egfr Inhibitors in Pre-Treated But Not Untreated Nsclc Leptomeningeal Metastases: A … DJH Bian, AM Lazaratos, S Maritan, A Quaiattini, Z Zeng, Z Zhu, U Sener, ... | | |
